AlphAIAlphAI — Financial news for AI agents
Stock TitanAPR 82 min read$NSRX

Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)

Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver have collectively reported a 5.2% beneficial ownership stake in Nasus Pharma Ltd (NSRX), totaling 612,913 Ordinary Shares each. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The ownership calculation is based on 11,710,808 shares outstanding as of March 27, 2026.

Original reporting
Stock Titan
Published Apr 8, 2026, 4:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 8, 2026, 4:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NSRX
Neutral
medium confidence
Mentioned
$NSRX
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$NSRXNeutralLow
01

Why it matters

This passive ownership suggests confidence but does not imply active trading signals. It may, however, support the stock's stability.

02

Market read

The passive ownership stake is unlikely to cause significant short-term trading activity but may influence long-term investor sentiment.

03

What to watch

Potential upcoming catalysts or company-specific news could alter the impact of this ownership stake.

Relevance 6/10Timing: low

Background

The disclosure of a 5.2% passive stake in NSRX by multiple funds indicates institutional interest, which is a common occurrence in the life sciences sector.

Company-level read

Ticker impact

$NSRXNeutralMedium confidence
Context

The disclosed passive ownership stake of 5.2% in Nasus Pharma Ltd (NSRX) indicates institutional interest, which could influence market perception.

Expected impact

Limited immediate price movement expected; potential for gradual appreciation if institutional interest sustains.

Evidence & confidence

Passive ownership disclosures typically reflect long-term interest rather than short-term trading signals. The low relevance score (0.318504) indicates minimal immediate impact on trading activity.

Market effects

Sector

Possible slight positive sentiment in the life sciences sector due to increased institutional interest.

Regional

Minimal regional impact; focus remains on company-specific developments.

Global

Low; this is a localized ownership disclosure with limited global market influence.

Counterpoint

What could challenge this read

Institutional ownership increase may not translate into positive price movement; could be a passive stake with no strategic intent.

Key entities

  • Institutional Investor
    Funicular Funds

    A fund that has disclosed a 2.0% stake in NSRX.

  • Institutional Investor
    Cable Car Capital

    A fund that has disclosed a 2.0% stake in NSRX.

  • Investor
    Jacob Ma-Weaver

    An individual investor with a 1.2% stake in NSRX.

  • Company
    Nasus Pharma Ltd

    A life sciences company focused on pharmaceutical development.

Read at source← All news

Related articles

SEP 29
$NSRXMedAI 8/10

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Nasus Pharma (NYSE: NSRX) has enrolled and dosed the first patient in a Phase 1 trial for NS003, its intranasal ondansetron formulation. Pre-clinical studies showed NS003's PK profile was comparable to IV ondansetron, with a favorable safety profile. The company aims to announce topline PK data before year-end and initiate a pivotal NS002 study for anaphylaxis in Q4. Ondansetron is widely used for chemotherapy-induced nausea and vomiting, with peak sales exceeding $1.5 billion in 2023.

globenewswire.com2 min
AUG 17
$NSRXMed

Nasus Pharma Ltd (NSRX): Financial results for H1 2026

Nasus Pharma Ltd (NSRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, August

SEC EDGAR 6-K2 min
OCT 23
$VLYMed

Keefe Bruyette upgrades Valley National stock rating on growth outlook

Keefe Bruyette upgraded Valley National Bancorp (VLY) to Outperform with a $17.00 price target, citing net interest income growth, valuation discount, and strong earnings metrics. The stock has a P/E ratio of 11.66, PEG ratio of 0.21, and a 3.19% dividend yield. VLY reported Q3 2026 earnings of $0.36 per share, beating estimates, with revenue of $584.15 million. The company expects to meet high-end guidance for 2026.

investing.com2 min